CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 394-401

  Li, Feng ^a   Lu, Jie ^a   Wang, Laiyou ^a,b   Ma, Xiaochao ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (PYRIDIN 2 YL)BENZAMIDO]ACETIC ACID; 2 ACETAMIDO 3 [4 (PYRIDIN 2 YL)BENZYLTHIO]PROPANOIC ACID; 4 (PYRIDIN 2 YL)BENZALDEHYDE; 4 (PYRIDIN 2 YL)BENZOIC ACID; ALDEHYDE; ALPHA HYDROXYALDEHYDE; ATAZANAVIR; BENZALDEHYDE; CYTOCHROME P450 3A; DRUG METABOLITE; HYDRAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG METABOLISM; FECES ANALYSIS; HUMAN; LIVER MICROSOME; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINALYSIS;

ALDEHYDES; ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; FECES; HIV PROTEASE INHIBITORS; HUMANS; HYDRAZINES; KETOCONAZOLE; METABOLOMICS; MICE; MICROSOMES, LIVER; OLIGOPEPTIDES; PYRIDINES; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; MUS;

EID: 79951869899     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036327     Document Type: Article

References (22)

1. Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889-893.
2. Busti AJ, Hall RG, and Margolis DM (2004) Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24:1732-1747. (Pubitemid 39578961)
3. Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, and Gonzalez FJ (2006) Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 318:1330-1342. (Pubitemid 44268343)
4. Croom KF, Dhillon S, and Keam SJ (2009) Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69:1107-1140.
5. Dieckhaus CM, Thompson CD, Roller SG, and Macdonald TL (2002) Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 142:99-117. (Pubitemid 35232556)
6. Eholié SP, Lacombe K, Serfaty L, Wendum D, and Girard PM (2004) Acute hepatic cytolysis in an HIV-infected patient taking atazanavir. AIDS 18:1610-1611. (Pubitemid 39037492)
7. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16. (Pubitemid 38134055)
8. Goldsmith DR and Perry CM (2003) Atazanavir. Drugs 63:1679-1693; discussion 1694-1675.
9. Guengerich FP and MacDonald JS (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 20:344-369. (Pubitemid 46548682)
10. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, et al. (2009) Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 50:290-293.
11. Havlir DV and O'Marro SD (2004) Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 38:1599-1604. (Pubitemid 38738558)
12. Ji T, Ikehata K, Koen YM, Esch SW, Williams TD, and Hanzlik RP (2007) Covalent modification of microsomal lipids by thiobenzamide metabolites in vivo. Chem Res Toxicol 20:701-708. (Pubitemid 46762105)
13. Li F, Wang L, Guo GL, and Ma X (2010) Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos 38:871-878.
14. Nicholls AW, Holmes E, Lindon JC, Shockcor JP, Farrant RD, Haselden JN, Damment SJ, Waterfield CJ, and Nicholson JK (2001) Metabonomic investigations into hydrazine toxicity in the rat. Chem Res Toxicol 14:975-987. (Pubitemid 32800153)
15. O'Brien PJ, Siraki AG, and Shangari N (2005) Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 35:609-662.
16. Rivas P, Morello J, Garrido C, Rodríguez-Nóvoa S, and Soriano V (2009) Role of atazanavir in the treatment of HIV infection. Ther Clin Risk Manag 5:99-116.
17. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
18. Sulkowski MS (2004) Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 38 (Suppl 2):S90-S97.
19. Swainston Harrison T and Scott LJ (2005) Atazanavir: a review of its use in the management of HIV infection. Drugs 65:2309-2336.
20. Tang W and Lu AY (2010) Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective. Drug Metab Rev 42:225-249.
21. ter Heine R, Hillebrand MJ, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, and Huitema AD (2009) Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor. Drug Metab Dispos 37:1826-1840.
22. Waterfield CJ, Turton JA, Scales MD, and Timbrell JA (1993) Investigations into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats. Arch Toxicol 67:244-254. (Pubitemid 23131831)